AHA 2025 shows LDL numbers are down, yet dangerous plaque remains. Repair Bio is pushing forward therapies that truly drain the sink through meaningful plaque regression.
Learn More Now! repairbiotechnologies.com/
#CardiovascularResearch #Atherosclerosis #Biotech #DrugDevelopment
“Developing a novel mRNA therapeutic for atherosclerotic cardiovascular disease requires strong manufacturing. AGC Biologics’ end-to-end expertise lowers risk and speeds GMP production for our trials. We’re proud to partner with them.”
— Reason, CEO and co-founder, Repair Bio
🧬 Breaking New Ground in Cardiovascular Therapy at AHA 2025 🧬
We’re thrilled to share that Repair Biotechnologies has presented compelling preclinical data at the American Heart Association (AHA) Scientific Sessions 2025.
repairbiotechnologies.com/re…
Did you know that one of the most persistent challenges in cardiovascular disease is the toxic cholesterol INSIDE your cells?
At Repair Bio, we’re not just slowing disease progression, we’re reversing it.
#PrecisionMedicine #BiotechInvesting #Cholesterol #Atherosclerosis
Today’s standard of care in atherosclerosis is built around lowering risk factors: statins, PCSK9 inhibitors, ezetimibe, and others.
At Repair Biotechnologies, we’re pioneering a different way to treat cardiovascular disease!
#Biotech #CardiovascularHealth #Atherosclerosis
Repair Bio is Part of The Future of Cardiovascular Disease Treatment
Read the ARK article here for context: ark-invest.com/articles/anal…
At Repair Biotechnologies, we’re addressing one of the world’s most critical unmet medical needs: arterial plaque.
See how Repair is tackling this problem through not just slowing growth, but regressing the plaque!
Follow us for updates as we advance this work.
#Biotech
🧬 What is HoFH? and Why Should You Care?
HoFH is a rare genetic disease causing dangerously high LDL cholesterol from birth – often leading to HEART ATTACKS BEFORE AGE 20.
🎥 Watch the video to see how we’re unlocking a major opportunity in cardiovascular care
🚨 Repair Biotechnologies Secures Orphan Drug Designation 🚨
The FDA's Orphan Drug Designation (ODD) isn’t just a regulatory win, it’s a commercial and strategic signal that the asset targets a serious unmet need with real potential!
🌟 Meet Bobby Khan, MD, PhD – Cardiovascular Trailblazer at Repair Biotechnologies ❤️🩹
Dr. Bobby Khan is the Chief Medical Officer at Repair Biotechnologies and a globally recognized leader in cardiology and translational medicine.
🌟 Meet Mourad Topors, PhD – Scientific Powerhouse Behind Repair Biotechnologies 🔬
Dr. Mourad Topors, Chief Scientific Officer at Repair Biotechnologies, brings over 20 years of groundbreaking research experience in molecular biology, aging, and cardiovascular disease.
🌟 Meet Reason - A Visionary in Longevity Biotechnology! 💡
Reason is the CEO and co-founder of Repair Biotechnologies, and is a driving force in the quest to end age-related diseases and extend the human lifespan.
repairbiotechnologies.com/te…
#Longevity #Biotech
